X

Bliss GVS Pharma Ltd Stock Analysis

Small Cap
Evaluated by 1123 users | BSE: 506197 | NSE: BLISSGVS |
Pharmaceuticals & Drugs

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bliss GVS Pharma Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 26.29%23.66%19.86%12.44%13.96%13.42%12.18%9.65%8.78%10.56%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 219267354288313326348298427442
Y-o-Y Gr. Rt.-22%32.4%-18.5%8.6%4.3%6.6%-14.4%43.2%3.6%
Adjusted EPS (Rs.) 3.884.224.863.85.055.45.775.155.377.1
Y-o-Y Gr. Rt.-8.8%15.2%-21.8%32.9%6.9%6.9%-10.8%4.3%32.2%
Book Value per Share (Rs.) 16.1520.424.8530.3935.6541.8947.6652.4958.4966.21
Adjusted Net Profit 4043.550.239.252.155.759.553.255.373.2
Net Op. Cash Flow (Rs. Cr.) 23.768.7-51.964.715.459.638.522.748.358
Debt to Cash Flow from Ops 0.350.09-1.461.335.851.361.964.141.481.52
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Bliss GVS Pharma Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 8.1%7.1%8.3%3.6%
Adjusted EPS 6.9%7.1%7.2%32.2%
Book Value per Share 1713.211.613.2
Share Price 17.3% -6.8% -22.1% -3.8%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 26.6823.0721.3813.6515.2613.9212.8810.299.6711.38
Operating Profit Margin (%) 26.8426.8428.5222.9227.5529.5929.0229.722.3822.66
Net Profit Margin (%) 18.2816.2914.1813.5816.6517.0617.0917.8512.9716.56
Debt to Equity 0.050.030.30.280.240.190.150.170.120.13
Working Capital Days 239231270508497527533621442443
Cash Conversion Cycle 147118100144154206206270269306
Entity Percentage Holding
Promoters 33.31%
Institutions 29.08%
Non-Institutions 37.61%
Pledged *0.000.000.000.000.000.000.000.000.330.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Bliss GVS Pharma Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Bliss GVS Pharma Ltd is a average quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Bliss GVS Pharma Ltd's performance infers:

Bliss GVS Pharma Ltd earnings have grown by 7.1%, whereas share price has depreciated -6.8% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Bliss GVS Pharma Ltd share prices over the last 10 years. Here is what we found out:

Bliss GVS Pharma Ltd share price has depreciated 13.7% annually over the past ten years.

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory,

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

  • 1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
  • 1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
  • 2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
  • 2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
  • 2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
  • 2011: EU-GMP approval to the manufacturing facility for suppository facility.
  • 2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
  • 2017: Setting up offices in South East Asian countries.
  • 2018: Divestment from Bliss GVS Healthcare.
  • 2019: Setting up of multi-dosage facility (Vevoor Plant).
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback